Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re: Ariad Pharmaceuticals, Inc. Securities Litigation
Case Number:
1:13-cv-12544
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Andrews DeValerio
- Berman Tabacco
- Bernstein Litowitz
- Goodwin Procter
- Matorin Law Office
- Milberg Coleman
- Mintz Levin
- Motley Rice
- Pastor Law Office
- Robbins Geller
- Shapiro Haber
- Thornton Law Firm LLP
Companies
Sectors & Industries:
-
May 10, 2018
3 Firms Win 25% Fee Approval For $3.5M Ariad Deal
A Massachusetts federal judge on Thursday afternoon gave his approval to a $3.5 million class action settlement between a group of investors and Takeda Pharmaceutical Co. unit Ariad Pharmaceuticals Inc., including a 25 percent cut plus expenses for the three firms that revived the suit and secured the deal.
-
April 06, 2018
Ariad Investors' Attys Seek 30% Of $3.5M Class Settlement
Attorneys who won the revival of a securities class action at the First Circuit in 2016 have requested exactly 30 percent of the $3.5 million settlement that their three law firms subsequently reached on behalf of investors with Takeda Pharmaceutical Co. unit Ariad Pharmaceuticals Inc.
-
November 30, 2017
Ariad, Investors Strike $3.5M Deal Over Cancer Drug Outlook
Takeda Pharmaceutical Co. Ltd. unit Ariad Pharmaceuticals Inc. has agreed to pay a proposed class of investors $3.5 million to settle claims it lied about the labeling prospects of its leukemia drug ponatinib, the investors told a Massachusetts federal court Wednesday.
-
March 25, 2015
Ariad, Execs Beat Fraud Suit Over Failed Leukemia Drug
Ariad Pharmaceuticals Inc. beat a securities fraud action Wednesday after a Boston federal judge said allegations that the company and four officers hid evidence suggesting a promising leukemia drug would fail were insufficient despite a "cogent argument" from investor-plaintiffs that defendants including CEO Harvey Berger engaged in insider trading.
-
May 22, 2014
Ariad Investors Decry Bid To Nix Failed Leukemia Drug Suit
Ariad Pharmaceuticals Inc. shareholders urged a Massachusetts federal judge to not toss a consolidated class action over alleged false statements about Ariad's failed leukemia drug Iclusig, saying Wednesday that prior to a $310 million insider stock sale, the oncology company's directors concealed evidence that the drug would fail.